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Aim: The present investigates deals with the change in the pharmacokinetic of Sildenafil citrate (SIL) in disease
condition like diabetic nephropathy (DN).
Method: Diabetes was induced in rats by administering Streptozotocin i.e. STZ (60 mg/kg, IP) saline solution.
Assessment of diabetes was done by GOD-POD method and conformation of DN was done by assessing the level
of Creatinine, Blood Urea Nitrogen (BUN) and Albuminurea. After the conformation of DN single dose of drug SIL
(2.5 mg/kg, p.o.) were given orally and Pharmacokinetic Parameters like [AUC o-t (ug.h/ml), AUC 0-∞, Cmax, Tmax, Kel,
Clast] were estimated in the plasma by the help of HPLC-UV.
Result: There was significant increase (p < 0.01) in the Pharmacokinetic parameters of SIL in DN rat (AUC0-t,
AUC0-∞, Cmax, Tmax and T1/2) compare to normal control rat and significant increase Kel in the DN rat compare to
control rat.
Conclusion: The study concluded that there was significant (p < 0.01) increase in the bioavailability of SIL in DN.
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Diabetes mellitus is a complex endocrine metabolic dis-
order. Globally, as of 2010, an estimated 285 million
people had diabetes, with type 2 making up about 90%
of the cases [1]. Its incidence is increasing rapidly, and
by 2030, this number is estimated to almost double [2].
India has more diabetics than any other country in the
world, according to the International Diabetes Foundation
[3]. Clinically, the main consequence of hyperglycemia is
secondary impairments in various tissues and organs.
Some complications such as cardio vascular disease, kid-
ney disease, retinopathy, and nervous system diseases
result in substantial morbidity and mortality [4]. What is
especially note worthy that the pharmacokinetic parame-
ters of many drugs are altered in diabetes [5-8]. The pos-
sible reasons for these pharmacokinetics changes are
diverse and complex, including gastrointestinal lesions* Correspondence: shloksk@gmail.com
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stated.which cause changes in drug absorption [9]; changes in
transporters responsible for uptake, efflux and elimination
[10]; changes in liver drug enzymes which alters metabolic
rate [11]; nephropathy which leads to changes of drug
transport, metabolism and elimination [12]. However, the
pharmacokinetic parameters of drugs are usually deter-
mined from healthy subjects. In clinical studies it has been
reported that drug accumulated in some diabetic patients
[13], and diabetes may influence pharmacodynamics and
increase the adverse effect of hypoglycemic agents. There-
fore, the study of drug pharmacokinetics in the diabetic
state is important and beneficial for clinical development.
Diabetic nephropathy (DN) is a progressive, irreversible
disease characterized by increasing blood pressure, micro-
albuminuria, proteinuria, and a continuous decline in
glomerular filtration rate [14]. There was number of drugs
used in the management of DN. Sildenafil citrate (SIL),
1-[4-ethoxy-3-(6, 7-dihydro-1-methyl-7-oxo-3-propyl-
1H- pyrazolo [4, 3-d] pyrimidin-5-yl) phenylsulfonyl] - 4
methylpiperazine, primarily indicated in the treatment
of erectile dysfunction [15]. It acts by inhibiting cGMP-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Effect of STZ on blood glucose level, Serum Creatinine, BUN and Albuminurea level in rats
Sr. no. Groups Blood glucose level (mg/dl) Serum creatinine (mg/dl) BUN level (mg/dl) Albuminurea (mg/day)
1 Control 108.00 ± 2.26 0.750 ± 0.07 10.89 ± 2.64 97.75 ± 0.25
2 Negative control (STZ) 289.66 ± 3.40@ 1.255 ± 0.07@ 20.39 ± 1.52@ 266.7 ± 0.20@
Data are the mean ± SEM for 6 rats,
@p < 0.01 compare to normal Control.
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motes degradation of cGMP, which regulates blood flow
in the penis. Literature suggest phosphodiesterase in-
hibitors type 5 (Sildenafil citrate) having role in the
management Diabetic Nephropathy So it is worthy to
check the change in the pharmacokinetics of SIL in Dia-
betic complication like DN [16].Material and methods
Animal
Healthy Male Sprague–Dawley rats (200–300 gm) were
used for the pharmacological screening. The animals
were housed in polypropylene cages with wire mesh top
and husk bedding and maintained under standard envir-
onmental conditions (25 ± 20C, relative humidity 60 ± 5%,
light- dark cycle of 12 hours each) and fed with standard
pellet diet (Trimurti feeds, Nagpur) and water ad libitum,
were used for the entire animal study. The rats were
housed and treated according to the rules and regulations
of CPCSEA and IAEC. The protocols for all the animal
studies were approved by the Institutional Animal Ethical
Committee (IAEC). CPCSEA registration no.- (650/02/C/
CPCSEA/08).Instrumentation
A double beam UV-Visible spectrophotometer, model
UV-2401 PC (Japan) with 10 mm matched quartz cell
was used.
The HPLC instrument consisted of Thermo separation
product quaternary gradient equipped with pump spectra
system P-4000 having inline membrane degasser. Detector
was a UV visible detector belonging to spectra system
UV 1000. Rheodyne 9725 injector with 20 μl loop. All
the data was processed using Data Ace software. Separ-
ation was achieved using a Prontosil C18 stationary
phase (150 7× 4.6 mm i.d. 5 μm particle size) and The
analytical column was protected by a Phenomenex C18
guard column (4 mm × 2.0 mm, i.d.).Table 2 Pharmacokinetic variables of SIL after oral adminis
diabetic rat
Sr. no. Group AUCo-t (ug.h/ml) AUC 0-∞
1 Control + SIL (2.5 mg/kg) 2.19 ± 0.052 0.5 ±
2 STZ + SIL (2.5 mg/kg) 3.72 ± 0.098* 1.12 ±
Data are the mean ± SEM for 6 rats,
*p < 0.01 compare to normal Control.Materials and reagents
Sildenafil citrate was donated by Ajanta Pharmaceuticals
pvt. ltd. All the reagent and chemical used were of AR
analytical & HPLC grade. Methanol (Spectrochem) and
water (Lobachem) used were of HPLC grade.Induction of diabetes
Diabetic rats were induced with an ip injection of
60 mg/kg of STZ (dissolved in pH 4.5 citrate buffer im-
mediately before injection), while controlled normal rats
(Control group, n = 6) received 2.5 mL/kg of citrate buf-
fer. Induction of the diabetic state was confirmed by
measuring the blood glucose level at the 72 h after the
injection of STZ. Rats with more than 200 mg/dl Blood
glucose level was conformation of diabetes. Blood glu-
cose level and biomarkers of nephropathy were checked
after 21 day for the conformation of Nephropathy. After
the conformation of Diabetic Nephropathy single dose
of drugs were given orally to the following groups and
the blood glucose level were checked. Group I: Control
group + SIL (2.5 mg/kg), Group II: Negative Control
(STZ) + SIL (2.5 mg/kg).Pharmacokinetic study
Single dose of SIL citrate was given orally to different
groups of rat for Pharmacokinetic studies. The rats were
fasted overnight with free access to water before admin-
istration of drugs. After a single oral administration of
SIL (2.5 mg/kg, p.o.), 0.5 ml of blood samples were col-
lected from retro orbital plexus sinus at 0.5, 1, 2, 4, 6, 12
and 24 h time-points. Plasma was separated by centrifu-
gation and stored at −20°C until analysis. Aliquots of
0.1 ml serum samples were processed on the developed
HPLC Method which was developed in our lab [17].
The pharmacokinetic parameters were calculated with
a Non-Compartmental model using Kinetica TM Soft-
ware (version 4.4.1 Thermo Electron Corporation, U.S.A).
Each value is expressed as Mean ± SD.tration at the dose of 2.5 mg/kg to control rats and
(ug.h/ml) C max (ug) Tmax (hr) Kel T1/2
0.02 0.8 ± 0.05 1 hr 0.10 ± 0.01 6.93
0.09* 1.1 ± 0.1* 1 hrns 0.089 ± 0.002* 8.6*
Figure 1 Mean serum concentration-time profile of SIL after
oral administration of 2.5 mg/kg of SIL in rats.
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Data were analyzed using Graph Pad Prism version 5.0 for
Windows (Graph Pad Software, San Diego, CA, USA).
Data were statistically analyzed using Student t test.
Result
Table 1 shows that there was significant increase (p < 0.01)
in the blood glucose level (289.66 ± 3.40), BUN (20.39 ±
1.52) and creatinine (1.255 ± 0.07) level in blood in STZ
treated rat as compare to Control group. Whereas STZ
treated group shows significant increase (p < 0.01)
Albumin urea (266.7 ± 0.20) level in the urine compare
to control group. These results confirm the nephropa-
thy induction.
Table 2 shows that the effect of Diabetic Nephropathy
on pharmacokinetic of SIL. The Pharmacokinetic param-
eters like AUC0-t, AUC0-∞, Cmax, Tmax, Kel and T1/2 were
assessed. There were significant increase (p < 0.01) in the
Pharmacokinetic parameters of SIL in DN rat (AUC0-t,
AUC0-∞, Cmax, Tmax and T1/2) compare to normal control
rat and significant increase Kel in the DN rat compare to
control rat. Figure 1 shows the serum concentration-time
profile of SIL after oral administration of 2.5 mg/kg of SIL
in rats.
Discussion
In the present study type 1 diabetes was induced by the
STZ in experimental rats [18] and the AUC and C max
of SIL were compared with control rat. Diabetic Ne-
phropathy was marked by increase in the Serum creatin-
ine, Blood urea nitrogen in blood and albumin urea in
urine [19]. In the present study diabetic nephropathy was
conformed as there were significant increases in these
values.
Sildenafil citrate is widely used as selective inhibitors of
cyclic guanosine monophosphate (cGMP)-specific phospho-
diesterase type 5 (PDE5) inhibitors in the treatment oferectile dysfunction (ED) [20,21]. They can also be effi-
cient as therapy for a range of cardiovascular diseases,
such as pulmonary arterial hypertension (PAH) [22-24].
The major route of elimination of sildenafil is hepatic me-
tabolism, with renal excretion of unchanged drug [25].
Diabetic patients have higher level of circulating glu-
cose in the blood, leading to non-enzymatic glycation of
several proteins including albumin. Glycated albumin
exhibits atherogenic effects in various cells [26]. Non-
enzymatic glycation of albumin produces conformational
changes in the structure of albumin (affinity of the
phenytoin binding site on albumin based on a modifica-
tion of the lysine group) [27], which can increase the
free fraction of acidic drugs in patients with type 1 and 2
diabetes (for more detail, see Table two) [28-35]. Worner
et al. [28] reported a 50% decrease in binding of dansyl-
sarcosine to albumin in diabetic patients, whereas the
concentration of circulating albumin was the same in
diabetic patients [36,37]. Glycation of blood and plasma
proteins leads to reduction in protein binding capacity
[38-40]. A linear relationship has been reported between
the degree of albumin glycation and the unbound frac-
tion of drug in the serum of diabetic patients. Thus, for
highly albumin bound acidic compounds the reduction
in the plasma serum protein binding capacity has been
shown in diabetic patients [41].
In DN and Control rat single dose of SIL was given or-
ally, and different pharmacokinetic parameters were
assessed. As DN leads to decrease in the GFR [42] and
protein content in the blood as there is microalbuminurea
in DN. This may increase the bioavailability of SIL in
DN rat. There was (Table 2) increase in the pharmaco-
kinetic parameters like AUC0-t, AUC0-∞, Cmax, Tmax,
Kel and T1/2 in DN rat compare to normal control rat.
Conclusion
Increase in the pharmacokinetic parameters of SIL con-
firms its increased bioavailability in DN rats.
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